All In Biotech

Drug Trial Radar · NCT07191028

Alzheimer's Disease THErapy With NEuroaid II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group Study to Assess the Efficacy and Safety of MLC901 (NeuroAiD™II) in Subjects With Mild to Moderate Alzheimer's Disease (AD).

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Feb 2029

Study completion May 2029

Sponsor

Lead sponsor
Moleac Pte Ltd.Industry
Sponsor type
Industry
Collaborators
National University Hospital, Singapore
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.

Conditions

  • Alzheimer's Disease Dementia

Interventions

  • MLC 901Drug

    Oral capsule, 2 capsules 3 times a day for 12 months

  • PlaceboDrug

    Oral capsule, 2 capsules 3 times a day for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale-Cognitive Subscale11 (ADAS-Cog11)Time frame: Baseline, Month 6 and Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National University Hospital Singapore

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.